Compare Godaddy Inc (GDDY) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Illumina, Inc. — how do they compare? Godaddy Inc trades at $105.15 (market cap $13.07B), while Illumina, Inc. trades at $269.34 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 3.1× Godaddy Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 65 Days and Illumina, Inc. for 83 Days on average.
| GDDY | ILMN | |
|---|---|---|
Market Cap | $13.07B | $39.95B |
Volume | 1,831,274 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $135.18 | $293.69 |
52-Week Low | $75.07 | $91.00 |
Typical Hold Time | 65 Days | 83 Days |
Enterprise Value | $15.75B | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $97.21, down 0.99% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with 63.8% gross margins and has beaten earnings estimates for three consecutive quarters. Revenue growth continues steadily from $4.95B in 2025 to projected $5.1B in 2026. Analyst consensus remains positive with 57.9% buy ratings and a $96.20 price target, though the stock faces headwinds from multiple securities class action lawsuits alleging misleading disclosures about domain pricing strategies.
The outlook remains cautiously optimistic given strong fundamentals and earnings momentum, but legal risks from ongoing securities litigation present significant near-term uncertainty. Investors should weigh the company's solid operational performance against potential legal liabilities and stock price volatility stemming from the class action proceedings with October 2026 deadlines.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
